These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 16085235)

  • 21. Microsatellite analysis of breast carcinoma and corresponding local recurrences.
    Regitnig P; Moser R; Thalhammer M; Luschin-Ebengreuth G; Ploner F; Papadi H; Tsybrovskyy O; Lax SF
    J Pathol; 2002 Oct; 198(2):190-7. PubMed ID: 12237878
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
    Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM
    Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
    Hussein MR; Abd-Elwahed SR; Abdulwahed AR
    Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recent advances and current controversies in the management of DCIS of the breast.
    Sakorafas GH; Farley DR; Peros G
    Cancer Treat Rev; 2008 Oct; 34(6):483-97. PubMed ID: 18490111
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The frequency of ipsilateral second tumors after breast-conserving surgery for DCIS: a population based analysis.
    Warren JL; Weaver DL; Bocklage T; Key CR; Platz CE; Cronin KA; Ballard-Barbash R; Willey SC; Harlan LC
    Cancer; 2005 Nov; 104(9):1840-8. PubMed ID: 16136599
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cell biological factors in ductal carcinoma in situ (DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics.
    Ringberg A; Anagnostaki L; Anderson H; Idvall I; Fernö M;
    Eur J Cancer; 2001 Aug; 37(12):1514-22. PubMed ID: 11506959
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Frozen section analysis for intraoperative margin assessment during breast-conserving surgery results in low rates of re-excision and local recurrence.
    Olson TP; Harter J; Muñoz A; Mahvi DM; Breslin T
    Ann Surg Oncol; 2007 Oct; 14(10):2953-60. PubMed ID: 17674109
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lobular neoplasia in breast core needle biopsy specimens is associated with a low risk of ductal carcinoma in situ or invasive carcinoma on subsequent excision.
    Renshaw AA; Derhagopian RP; Martinez P; Gould EW
    Am J Clin Pathol; 2006 Aug; 126(2):310-3. PubMed ID: 16891208
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relation between the method of detection of initial breast carcinoma and the method of detection of subsequent ipsilateral local recurrence and contralateral breast carcinoma.
    Chen C; Orel SG; Harris EE; Hwang WT; Solin LJ
    Cancer; 2003 Oct; 98(8):1596-602. PubMed ID: 14534874
    [TBL] [Abstract][Full Text] [Related]  

  • 30. p53 overexpression is a predictor of local recurrence after treatment for both in situ and invasive ductal carcinoma of the breast.
    de Roos MA; de Bock GH; de Vries J; van der Vegt B; Wesseling J
    J Surg Res; 2007 Jun; 140(1):109-14. PubMed ID: 17291532
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ductal carcinoma in situ of the breast -- among factors predicting for recurrence, distance from the nipple is important.
    Stallard S; Hole DA; Purushotham AD; Hiew LY; Mehanna H; Cordiner C; Dobson H; Mallon EA; George WD
    Eur J Surg Oncol; 2001 Jun; 27(4):373-7. PubMed ID: 11417983
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Survivin expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence.
    Barnes N; Haywood P; Flint P; Knox WF; Bundred NJ
    Br J Cancer; 2006 Jan; 94(2):253-8. PubMed ID: 16421596
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patterns of chromosomal alterations in breast ductal carcinoma in situ.
    Hwang ES; DeVries S; Chew KL; Moore DH; Kerlikowske K; Thor A; Ljung BM; Waldman FM
    Clin Cancer Res; 2004 Aug; 10(15):5160-7. PubMed ID: 15297420
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up.
    Di Saverio S; Catena F; Santini D; Ansaloni L; Fogacci T; Mignani S; Leone A; Gazzotti F; Gagliardi S; De Cataldis A; Taffurelli M
    Breast Cancer Res Treat; 2008 Jun; 109(3):405-16. PubMed ID: 17687650
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factors predicting in-breast tumor recurrence after breast-conserving surgery.
    Mechera R; Viehl CT; Oertli D
    Breast Cancer Res Treat; 2009 Jul; 116(1):171-7. PubMed ID: 18815880
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.
    Park K; Han S; Kim HJ; Kim J; Shin E
    Histopathology; 2006 May; 48(6):702-7. PubMed ID: 16681686
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Breast carcinoma in women 35 years and younger: a pathological study.
    Fernandopulle SM; Cher-Siangang P; Tan PH
    Pathology; 2006 Jun; 38(3):219-22. PubMed ID: 16753742
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: twelve-year observations concerning lobular carcinoma in situ.
    Fisher ER; Land SR; Fisher B; Mamounas E; Gilarski L; Wolmark N
    Cancer; 2004 Jan; 100(2):238-44. PubMed ID: 14716756
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 8. The dilemma of in situ carcinoma of the breast.
    Fentiman IS
    Int J Clin Pract; 2001 Dec; 55(10):680-3. PubMed ID: 11777293
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome.
    Mazouni C; Peintinger F; Wan-Kau S; Andre F; Gonzalez-Angulo AM; Symmans WF; Meric-Bernstam F; Valero V; Hortobagyi GN; Pusztai L
    J Clin Oncol; 2007 Jul; 25(19):2650-5. PubMed ID: 17602071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.